NCT05479708Active, not recruiting
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Postoperative ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma: A Prospective Observational Cohort Study
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
Short-term relapse and poor survival are prevalent in patients with pancreatic adenocarcinoma (PAAD) after surgeries. Despite the importance of adjuvant treatments for resected PAAD patients, there is currently no suitable biomarker to identify those individuals with high risk of recurrence and inform therapeutic decision making. In this study, we aim to examine whether postoperative circulating tumor DNA (ctDNA) could be used as a biomarker for early detection of minimal residual disease (MRD) and predicting relapse in resected PAAD through high-depth targeted next-generation sequencing.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 28 Jul 2022
- Start date
- 9 Aug 2023
- Primary completion date
- Jan 2028
- Lead sponsor
- BAIYONG SHEN
- Diseases
- Pancreatic cancer
- NCT number
- NCT05479708
What you commit to
- Study type: Observational
- Planned participants: 150
- From 9 Aug 2023 to the primary completion date, Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving neo-adjuvant therapy before surgery
- Imaging recurrence/metastasis or CA 19-9\>37 U/ml in postoperative 4-8 weeks (before adjuvant chemotherapy)
- Prior transplantation of bone marrow, stem cell or organ
Other illness
- With serious internal medicine diseases, infectious diseases, other solid tumors (except PAAD) or hematologic disorders
- Distant organ metastasis or malignant ascites
Other
- Pregnant or breastfeeding at time of enrollment
Who the study is looking for
- Pathologically diagnosed pancreatic adenocarcinoma (stage I-III)
- KRAS mutations identified in resected tumor tissues
- Margin negative (R0) or no imaging recurrence/metastasis and CA 19-9\<37 U/ml in postoperative 4-8 weeks (before adjuvant chemotherapy)
- Receiving adjuvant chemotherapy
- ECOG 0-2
- Signed informed consent
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.